URGN

News UroGen settles with Teva over Jelmyto patent dispute

4h ago

SEC filing URGN Secures Non‑Exclusive Jelmyto License, Blocks Teva Launch Until 2030, Ends Patent Fight

5h ago

News Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?

14d ago

News Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday

14d ago

Insider trade Sale by Mark Schoenberg (Chief Medical Officer)

21d ago

SEC filing URGN Reports $29.2M ZUSDURI Revenue, 109% QoQ Growth, $21.7M JELMYTO Revenue, 7% YoY Growth

27d ago

News UroGen outlines $1B peak revenue goal for ZUSDURI amid accelerated adoption and expanded pipeline

91d ago

SEC filing URGN Secures $250M Term Loan, Funds $200M Tranche A, Refinances $125M Debt

92d ago

Insider trade Sale by Mark Schoenberg (Chief Medical Officer)

104d ago